Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy

Imatinib-based targeted treatment is the standard therapy for chronic myeloid leukemia (CML); however, drug resistance is an inevitable issue for imatinib-based CML treatment. Imatinib resistance can be ascribed to Bcr-Abl-dependent and independent resistance. In the present study, peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chunshui, Li, Yuying, Hu, Ruiping, Han, Wei, Gao, Sujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610035/
https://www.ncbi.nlm.nih.gov/pubmed/31233186
http://dx.doi.org/10.3892/or.2019.7194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610035/
https://www.ncbi.nlm.nih.gov/pubmed/31233186
http://dx.doi.org/10.3892/or.2019.7194

Ejemplares similares